Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
$6.84
-$0.34(-1.95%)
At close: 4:00 PM EST
$6.84
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.98 - $20.00
Previous CloseN/A
Volume45.37K
Average Volume (3M)131.91K
Market Cap
$177.86M
Enterprise Value$32.52M
Total Cash (Recent Filing)$143.38M
Total Debt (Recent Filing)$12.60M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Mar 05, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding26,003,607
10 Day Avg. Volume84,774
30 Day Avg. Volume131,913
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-68.21
Price to Sales (P/S)11.92
P/FCF Ratio-14.16
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue29.81
Enterprise Value/Gross Profit-2.78
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$35.00Price Target Upside411.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$672.57K
Bulls Say, Bears Say
Bulls Say
Phase III EnrollmentOngoing Phase III AURORA enrollment for Descartes-08 in generalized myasthenia gravis supports a potentially pivotal outcome with a planned clinical readout in 2027 and draws on strong Phase II efficacy to reduce late-stage risk.
Pipeline Expansion And Mechanism SupportRegulatory acceptance of an IND for myositis, initiation of a pediatric basket study, and early lupus biomarker responses provide clinical and mechanistic signals that could support expansion into multiple autoimmune and pediatric indications.
Safety And Administration AdvantagesMRNA-based Descartes-08 can be administered in outpatient and community settings without lymphodepletion, which lowers treatment-related risks and could enable broader patient access compared with DNA CAR-T approaches.
Bears Say
Difficulty And Competition In Lupus IndicationsSLE and lupus nephritis present recruitment challenges and intense competition for cell therapies, increasing clinical complexity and commercial uncertainty for programs targeting those indications.
Program Pauses And Pipeline NarrowingStrategic pauses in systemic lupus development and discontinuation of Descartes-15 concentrate resources on lead indications but narrow the developmental pipeline and reduce product diversification.
Safety Risks With T-cell EngagersAcknowledged risks of cytokine release syndrome, neurotoxicity, and severe infections associated with T-cell engager approaches may limit use of related therapies and invite heightened regulatory and clinical management burdens.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $5.98 and its highest was $20.00 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $177.86M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 27 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.847 by -$0.533.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 26,003,607 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.847. Following the earnings report the stock price went down -1.565%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (411.70% Upside)
$35.00 (411.70% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.8%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.15%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$35.00
▲(411.70% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
42.20% Insiders
10.98% Mutual Funds
6.09% Other Institutional Investors
37.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---